PriceTargets.com logo

LON:HIK - Hikma Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 2,416.67
  • Forecasted Upside: 47.54 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,638 As of 07/5/2022 01:00 AM ET
▼ -16 (-0.97%)

This chart shows the closing price for HIK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HIK

Analyst Price Target is GBX 2,416.67
▲ +47.54% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 2,416.67, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a 47.54% upside from the last price of GBX 1,638.

This chart shows the closing price for HIK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Hikma Pharmaceuticals. This rating has held steady since December 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/4/2022BarclaysReiterated RatingOverweightGBX 2,500
6/1/2022BarclaysReiterated RatingOverweightGBX 2,500
5/25/2022JPMorgan Chase & Co.DowngradeNeutralGBX 2,900 ➝ GBX 1,900
5/24/2022BarclaysReiterated RatingOverweightGBX 2,500
5/11/2022Morgan StanleyReiterated RatingEqual Weight
5/9/2022BarclaysReiterated RatingOverweightGBX 2,800
4/29/2022BarclaysReiterated RatingOverweightGBX 2,800
4/14/2022BarclaysReiterated RatingOverweightGBX 2,800
4/4/2022BarclaysReiterated RatingOverweightGBX 2,800
3/15/2022BarclaysReiterated RatingOverweightGBX 2,800
3/7/2022BarclaysReiterated RatingOverweightGBX 2,800
3/3/2022Morgan StanleyDowngradeEqual WeightGBX 2,800 ➝ GBX 2,300
2/21/2022BarclaysReiterated RatingOverweightGBX 2,800
2/9/2022Morgan StanleyReiterated RatingOverweight
2/9/2022BarclaysLower Price TargetOverweightGBX 3,000 ➝ GBX 2,800
1/24/2022BarclaysReiterated RatingOverweightGBX 7,000
1/17/2022JPMorgan Chase & Co.Reiterated RatingOverweight
1/4/2022JPMorgan Chase & Co.Reiterated RatingOverweight
12/17/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/1/2021CitigroupReiterated RatingBuyGBX 2,880
10/20/2021BarclaysBoost Price TargetOverweightGBX 2,900 ➝ GBX 3,000
9/2/2021BarclaysBoost Price TargetOverweightGBX 2,800 ➝ GBX 2,900
7/19/2021BarclaysReiterated RatingOverweightGBX 2,800
5/6/2021BarclaysReiterated RatingOverweightGBX 2,800
2/1/2021CitigroupReiterated RatingBuy
9/2/2020CitigroupReiterated RatingBuy
7/30/2020Peel HuntBoost Price TargetBuyGBX 2,380 ➝ GBX 2,860
7/7/2020Morgan StanleyUpgradeOverweightGBX 2,200 ➝ GBX 2,600
7/2/2020Peel HuntReiterated RatingBuy
6/23/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/22/2020Peel HuntReiterated RatingBuy
4/30/2020Peel HuntReiterated RatingBuy
4/28/2020BarclaysBoost Price TargetEqual WeightGBX 1,950 ➝ GBX 2,200
4/24/2020The Goldman Sachs GroupDowngradeNeutralGBX 2,200 ➝ GBX 2,400
4/24/2020Peel HuntReiterated RatingBuy
4/3/2020CitigroupBoost Price TargetBuyGBX 2,150 ➝ GBX 2,500
4/2/2020JPMorgan Chase & Co.UpgradeOverweightGBX 1,850 ➝ GBX 2,400
4/2/2020Peel HuntUpgradeBuyGBX 1,990 ➝ GBX 2,380
3/31/2020Peel HuntReiterated RatingHold
3/12/2020Jefferies Financial GroupBoost Price TargetBuyGBX 2,300 ➝ GBX 2,390
3/10/2020CitigroupUpgradeBuyGBX 1,980 ➝ GBX 2,150
3/5/2020Peel HuntReiterated RatingHold
3/2/2020BarclaysBoost Price TargetEqual weightGBX 1,900 ➝ GBX 1,950
2/28/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
2/28/2020CitigroupReiterated RatingNeutral
2/24/2020Peel HuntReiterated RatingHold
2/20/2020BarclaysReiterated RatingEqual weight
2/18/2020Peel HuntReiterated RatingHold
2/17/2020CitigroupDowngradeNeutral
2/5/2020Peel HuntReiterated RatingHold
1/27/2020Peel HuntReiterated RatingHold
1/21/2020Jefferies Financial GroupLower Price TargetBuyGBX 2,310 ➝ GBX 2,240
1/20/2020BarclaysReiterated RatingEqual WeightGBX 1,900
1/10/2020Peel HuntReiterated RatingHold
1/6/2020JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,800 ➝ GBX 1,850
12/6/2019BarclaysReiterated RatingEqual weight
12/5/2019Peel HuntReiterated RatingHold
12/3/2019JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,700 ➝ GBX 1,800
11/27/2019Peel HuntReiterated RatingHold
11/27/2019HSBCReiterated RatingReduce
11/18/2019BarclaysReiterated RatingEqual weight
11/15/2019Jefferies Financial GroupReiterated RatingBuy
11/13/2019Morgan StanleyReiterated RatingEqual weight
11/7/2019CitigroupReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingHold
9/2/2019Peel HuntReiterated RatingHold
8/20/2019BarclaysBoost Price TargetEqual weightGBX 1,800 ➝ GBX 1,900
8/9/2019Peel HuntReiterated RatingHoldGBX 1,870 ➝ GBX 2,050
7/29/2019Peel HuntReiterated RatingHold
7/3/2019Peel HuntReiterated RatingHold
6/18/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,700
6/4/2019Peel HuntReiterated RatingHold
5/17/2019Peel HuntReiterated RatingHold
5/3/2019BarclaysReiterated RatingEqual WeightGBX 1,800
5/2/2019Peel HuntReiterated RatingHold
4/10/2019BarclaysReiterated RatingEqual weight
4/2/2019Peel HuntReiterated RatingHold
3/21/2019BarclaysLower Price TargetEqual weightGBX 1,950 ➝ GBX 1,800
3/19/2019CitigroupUpgradeBuy
3/19/2019Jefferies Financial GroupLower Price TargetBuyGBX 2,000 ➝ GBX 1,960
3/14/2019HSBCBoost Price TargetReduceGBX 1,225 ➝ GBX 1,350
3/14/2019JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,800 ➝ GBX 1,700
3/13/2019Numis SecuritiesReiterated RatingHoldGBX 1,730
3/12/2019Peel HuntLower Price TargetHoldGBX 2,000 ➝ GBX 1,870
1/31/2019Peel HuntReiterated RatingHold
1/21/2019BarclaysReiterated RatingEqual weight
1/15/2019BarclaysReiterated RatingEqual weight
1/7/2019Peel HuntReiterated RatingHold
1/2/2019JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,900 ➝ GBX 1,800
12/19/2018BarclaysReiterated RatingEqual weight
12/7/2018BarclaysReiterated RatingEqual weight
12/6/2018Peel HuntReiterated RatingHold
11/27/2018Jefferies Financial GroupUpgradeBuyGBX 1,643 ➝ GBX 2,000
11/20/2018JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,050 ➝ GBX 1,900
11/12/2018Peel HuntDowngradeHoldGBX 1,950 ➝ GBX 2,000
11/9/2018BarclaysReiterated RatingEqual WeightGBX 1,950
11/8/2018Peel HuntReiterated RatingAdd
11/6/2018BarclaysUpgradeEqual weightGBX 1,400 ➝ GBX 1,800
11/1/2018Peel HuntReiterated RatingAdd
10/30/2018CitigroupReiterated RatingBuyGBX 2,250
10/23/2018Peel HuntReiterated RatingAdd
10/15/2018BarclaysReiterated RatingUnderweight
10/9/2018BarclaysReiterated RatingUnderweight
10/3/2018Peel HuntReiterated RatingAdd
10/3/2018CitigroupBoost Price TargetBuyGBX 2,100 ➝ GBX 2,250
9/24/2018BarclaysReiterated RatingUnderweight
9/17/2018BarclaysReiterated RatingUnderweight
9/4/2018Peel HuntReiterated RatingAdd
8/24/2018BarclaysReiterated RatingUnderweightGBX 1,400
8/21/2018JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,050
8/20/2018CitigroupBoost Price TargetBuyGBX 1,675 ➝ GBX 2,100
8/16/2018BarclaysReiterated RatingUnderweight
8/16/2018Peel HuntUpgradeAddGBX 1,160 ➝ GBX 1,950
8/15/2018Numis SecuritiesReiterated RatingHold
8/15/2018Peel HuntReiterated RatingHoldGBX 1,160
8/10/2018BarclaysReiterated RatingUnderweight
8/9/2018Numis SecuritiesDowngradeHoldGBX 1,560
8/1/2018Peel HuntReiterated RatingHold
7/19/2018BarclaysReiterated RatingUnderweight
7/10/2018BarclaysReiterated RatingUnderweight
7/3/2018CitigroupReiterated RatingBuyGBX 1,675
7/3/2018Peel HuntReiterated RatingHold
5/31/2018Peel HuntReiterated RatingHold
5/21/2018BarclaysReiterated RatingUnderweight
5/18/2018Numis SecuritiesDowngradeAddGBX 1,300 ➝ GBX 1,560
5/18/2018Jefferies Financial GroupReiterated RatingHoldGBX 997
5/18/2018Peel HuntReiterated RatingHold
5/1/2018CitigroupBoost Price TargetBuyGBX 1,250 ➝ GBX 1,475
4/4/2018Peel HuntReiterated RatingHold
3/20/2018Peel HuntLower Price TargetHoldGBX 1,180 ➝ GBX 1,160
3/19/2018BarclaysReiterated RatingUnderweightGBX 800 ➝ GBX 850
3/15/2018Morgan StanleyBoost Price TargetEqual weightGBX 1,000 ➝ GBX 1,050
3/15/2018CitigroupUpgradeBuyGBX 1,250
3/15/2018JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,000 ➝ GBX 1,050
3/15/2018Jefferies Financial GroupUpgradeHoldGBX 895 ➝ GBX 997
3/14/2018Peel HuntReiterated RatingHoldGBX 1,180
3/14/2018Numis SecuritiesInitiated CoverageBuyGBX 1,300
3/1/2018BarclaysDowngradeUnderweightGBX 1,500 ➝ GBX 800
2/15/2018Peel HuntLower Price TargetHoldGBX 1,390 ➝ GBX 1,180
2/1/2018Peel HuntReiterated RatingHoldGBX 1,390
1/17/2018Jefferies Financial GroupReiterated RatingUnderperformGBX 895
1/15/2018JPMorgan Chase & Co.Reiterated RatingNeutral
1/10/2018Jefferies Financial GroupDowngradeUnderperformGBX 1,074 ➝ GBX 895
12/20/2017Numis SecuritiesReiterated RatingBuyGBX 1,300
12/4/2017Jefferies Financial GroupBoost Price TargetHoldGBX 1,045 ➝ GBX 1,074
12/1/2017Morgan StanleyReiterated RatingEqual weightGBX 1,100
11/15/2017Peel HuntReiterated RatingHoldGBX 1,390
11/10/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,250 ➝ GBX 1,000
11/9/2017Peel HuntReiterated RatingHoldGBX 1,390
11/9/2017Stifel NicolausLower Price TargetHoldGBX 1,320 ➝ GBX 1,000
11/9/2017Numis SecuritiesUpgradeBuyGBX 1,300
11/9/2017Jefferies Financial GroupReiterated RatingHoldGBX 1,045
10/31/2017Peel HuntReiterated RatingHoldGBX 1,390
10/6/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,500 ➝ GBX 1,250
9/29/2017JPMorgan Chase & Co.Reiterated RatingNeutral
8/29/2017Stifel NicolausDowngradeHoldGBX 2,300 ➝ GBX 1,320
8/25/2017BarclaysLower Price TargetOverweightGBX 2,200 ➝ GBX 1,500
8/24/2017CitigroupReiterated RatingNeutralGBX 1,350
8/22/2017The Goldman Sachs GroupDowngradeNeutralGBX 2,600 ➝ GBX 1,310
8/21/2017Morgan StanleyDowngradeEqual weightGBX 1,600 ➝ GBX 1,350
8/21/2017Jefferies Financial GroupLower Price TargetHoldGBX 1,390 ➝ GBX 1,045
8/17/2017Numis SecuritiesReiterated RatingAddGBX 1,560
8/17/2017Peel HuntReiterated RatingHoldGBX 2,150
8/11/2017Numis SecuritiesReiterated RatingAddGBX 1,560
8/2/2017Morgan StanleyDowngradeEqual WeightGBX 2,050 ➝ GBX 1,600
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/7/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/6/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/5/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Hikma Pharmaceuticals logo
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Read More

Today's Range

Now: GBX 1,638
Low: 1,615.50
High: 1,667.50

50 Day Range

MA: GBX 1,679.43
Low: 1,482
High: 2,015.83

52 Week Range

Now: GBX 1,638
Low: 1,459.50
High: 2,703

Volume

325,026 shs

Average Volume

704,199 shs

Market Capitalization

£3.61 billion

P/E Ratio

1,099.33

Dividend Yield

2.36%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Hikma Pharmaceuticals in the last twelve months: Barclays PLC, Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, Peel Hunt, and Peel Hunt LLP.
View the latest analyst ratings for HIK.

What is the current price target for Hikma Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year. Their average twelve-month price target is GBX 2,416.67, suggesting a possible upside of 47.5%.
View the latest price targets for HIK.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HIK, but not buy more shares or sell existing shares.
View the latest ratings for HIK.

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company's listed phone number is +44-20-73992760. The official website for Hikma Pharmaceuticals is www.hikma.com. Learn More about contacing Hikma Pharmaceuticals investor relations.